Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine whether the drug sirolimus reduces the
likelihood of developing of pulmonary fibrosis in patients who are hospitalized with COVID-19
pneumonia.